A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated and certain top executives in U.S. federal court, seeking to recover investor losses tied to purchases of Corcept common stock between October 31, 2024, and December 30, 2025. The complaint alleges the company misled the market about the regulatory prospects for its lead drug candidate relacorilant by downplaying FDA concerns about the adequacy of its clinical data. Corcept disclosed on December 31, 2025 that it received a Complete Response Letter from the FDA, after which the stock fell sharply; a lead plaintiff deadline has been set for April 21, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602231422PRIMZONEFULLFEED9659443) on February 23, 2026, and is solely responsible for the information contained therein.